Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

MIR142 Loss-of-Function Mutations Derepress ASH1L to Increase HOXA Gene Expression and Promote Leukemogenesis.

Trissal MC, Wong TN, Yao JC, Ramaswamy R, Kuo I, Baty J, Sun Y, Jih G, Parikh N, Berrien-Elliott MM, Fehniger TA, Ley TJ, Maillard I, Reddy PR, Link DC.

Cancer Res. 2018 Jul 1;78(13):3510-3521. doi: 10.1158/0008-5472.CAN-17-3592. Epub 2018 May 3.

PMID:
29724719
2.

A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.

Fehniger TA, Miller JS, Stuart RK, Cooley S, Salhotra A, Curtsinger J, Westervelt P, DiPersio JF, Hillman TM, Silver N, Szarek M, Gorelik L, Lowdell MW, Rowinsky E.

Biol Blood Marrow Transplant. 2018 Mar 27. pii: S1083-8791(18)30132-0. doi: 10.1016/j.bbmt.2018.03.019. [Epub ahead of print]

PMID:
29597002
3.

Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow.

Bansal D, Vij K, Chang GS, Miller CA, DiPersio JF, Vij R, Heath SE, Westervelt P, Welch JS, Fehniger TA.

Haematologica. 2018 Jun;103(6):e270-e273. doi: 10.3324/haematol.2017.184168. Epub 2018 Mar 22. No abstract available.

4.

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.

Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, Weisdorf DJ, Blazar BR, Ustun C, DeFor TE, Vivek S, Peck L, DiPersio JF, Cashen AF, Kyllo R, Musiek A, Schaffer A, Anadkat MJ, Rosman I, Miller D, Egan JO, Jeng EK, Rock A, Wong HC, Fehniger TA, Miller JS.

Blood. 2018 Jun 7;131(23):2515-2527. doi: 10.1182/blood-2017-12-823757. Epub 2018 Feb 20.

PMID:
29463563
5.

Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination? Vaccination Strategies Based on NK Cell and ILC Memory.

Cooper MA, Fehniger TA, Colonna M.

Cold Spring Harb Perspect Biol. 2017 Dec 18. pii: a029512. doi: 10.1101/cshperspect.a029512. [Epub ahead of print]

PMID:
29254976
6.

Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control.

Mah AY, Rashidi A, Keppel MP, Saucier N, Moore EK, Alinger JB, Tripathy SK, Agarwal SK, Jeng EK, Wong HC, Miller JS, Fehniger TA, Mace EM, French AR, Cooper MA.

JCI Insight. 2017 Dec 7;2(23). pii: 95128. doi: 10.1172/jci.insight.95128. [Epub ahead of print]

7.

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.

Bartlett NL, Costello BA, LaPlant BR, Ansell SM, Kuruvilla JG, Reeder CB, Thye LS, Anderson DM, Krysiak K, Ramirez C, Qi J, Siegel BA, Griffith M, Griffith OL, Gomez F, Fehniger TA.

Blood. 2018 Jan 11;131(2):182-190. doi: 10.1182/blood-2017-09-804641. Epub 2017 Oct 26.

PMID:
29074501
8.

Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.

Ali AM, Weisel D, Gao F, Uy GL, Cashen AF, Jacoby MA, Wartman LD, Ghobadi A, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Schroeder MA, Westervelt P, DiPersio JF, Welch JS.

Cancer Med. 2017 Dec;6(12):2814-2821. doi: 10.1002/cam4.1231. Epub 2017 Oct 23.

9.

Guidelines for the use of flow cytometry and cell sorting in immunological studies.

Cossarizza A, Chang HD, Radbruch A, Akdis M, Andrä I, Annunziato F, Bacher P, Barnaba V, Battistini L, Bauer WM, Baumgart S, Becher B, Beisker W, Berek C, Blanco A, Borsellino G, Boulais PE, Brinkman RR, Büscher M, Busch DH, Bushnell TP, Cao X, Cavani A, Chattopadhyay PK, Cheng Q, Chow S, Clerici M, Cooke A, Cosma A, Cosmi L, Cumano A, Dang VD, Davies D, De Biasi S, Del Zotto G, Della Bella S, Dellabona P, Deniz G, Dessing M, Diefenbach A, Di Santo J, Dieli F, Dolf A, Donnenberg VS, Dörner T, Ehrhardt GRA, Endl E, Engel P, Engelhardt B, Esser C, Everts B, Dreher A, Falk CS, Fehniger TA, Filby A, Fillatreau S, Follo M, Förster I, Foster J, Foulds GA, Frenette PS, Galbraith D, Garbi N, García-Godoy MD, Geginat J, Ghoreschi K, Gibellini L, Goettlinger C, Goodyear CS, Gori A, Grogan J, Gross M, Grützkau A, Grummitt D, Hahn J, Hammer Q, Hauser AE, Haviland DL, Hedley D, Herrera G, Herrmann M, Hiepe F, Holland T, Hombrink P, Houston JP, Hoyer BF, Huang B, Hunter CA, Iannone A, Jäck HM, Jávega B, Jonjic S, Juelke K, Jung S, Kaiser T, Kalina T, Keller B, Khan S, Kienhöfer D, Kroneis T, Kunkel D, Kurts C, Kvistborg P, Lannigan J, Lantz O, Larbi A, LeibundGut-Landmann S, Leipold MD, Levings MK, Litwin V, Liu Y, Lohoff M, Lombardi G, Lopez L, Lovett-Racke A, Lubberts E, Ludewig B, Lugli E, Maecker HT, Martrus G, Matarese G, Maueröder C, McGrath M, McInnes I, Mei HE, Melchers F, Melzer S, Mielenz D, Mills K, Mirrer D, Mjösberg J, Moore J, Moran B, Moretta A, Moretta L, Mosmann TR, Müller S, Müller W, Münz C, Multhoff G, Munoz LE, Murphy KM, Nakayama T, Nasi M, Neudörfl C, Nolan J, Nourshargh S, O'Connor JE, Ouyang W, Oxenius A, Palankar R, Panse I, Peterson P, Peth C, Petriz J, Philips D, Pickl W, Piconese S, Pinti M, Pockley AG, Podolska MJ, Pucillo C, Quataert SA, Radstake TRDJ, Rajwa B, Rebhahn JA, Recktenwald D, Remmerswaal EBM, Rezvani K, Rico LG, Robinson JP, Romagnani C, Rubartelli A, Ruckert B, Ruland J, Sakaguchi S, Sala-de-Oyanguren F, Samstag Y, Sanderson S, Sawitzki B, Scheffold A, Schiemann M, Schildberg F, Schimisky E, Schmid SA, Schmitt S, Schober K, Schüler T, Schulz AR, Schumacher T, Scotta C, Shankey TV, Shemer A, Simon AK, Spidlen J, Stall AM, Stark R, Stehle C, Stein M, Steinmetz T, Stockinger H, Takahama Y, Tarnok A, Tian Z, Toldi G, Tornack J, Traggiai E, Trotter J, Ulrich H, van der Braber M, van Lier RAW, Veldhoen M, Vento-Asturias S, Vieira P, Voehringer D, Volk HD, von Volkmann K, Waisman A, Walker R, Ward MD, Warnatz K, Warth S, Watson JV, Watzl C, Wegener L, Wiedemann A, Wienands J, Willimsky G, Wing J, Wurst P, Yu L, Yue A, Zhang Q, Zhao Y, Ziegler S, Zimmermann J.

Eur J Immunol. 2017 Oct;47(10):1584-1797. doi: 10.1002/eji.201646632. No abstract available.

PMID:
29023707
10.

CD56bright NK cells exhibit potent antitumor responses following IL-15 priming.

Wagner JA, Rosario M, Romee R, Berrien-Elliott MM, Schneider SE, Leong JW, Sullivan RP, Jewell BA, Becker-Hapak M, Schappe T, Abdel-Latif S, Ireland AR, Jaishankar D, King JA, Vij R, Clement D, Goodridge J, Malmberg KJ, Wong HC, Fehniger TA.

J Clin Invest. 2017 Nov 1;127(11):4042-4058. doi: 10.1172/JCI90387. Epub 2017 Oct 3.

11.

CD70 turns on NK cells to attack lymphoma.

Fehniger TA.

Blood. 2017 Jul 20;130(3):238-239. doi: 10.1182/blood-2017-06-786244. No abstract available.

12.

A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.

Maly JJ, Christian BA, Zhu X, Wei L, Sexton JL, Jaglowski SM, Devine SM, Fehniger TA, Wagner-Johnston ND, Phelps MA, Bartlett NL, Blum KA.

Clin Lymphoma Myeloma Leuk. 2017 Jun;17(6):347-353. doi: 10.1016/j.clml.2017.05.008. Epub 2017 May 22.

13.

T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia.

How J, Slade M, Vu K, DiPersio JF, Westervelt P, Uy GL, Abboud CN, Vij R, Schroeder MA, Fehniger TA, Romee R.

Biol Blood Marrow Transplant. 2017 Apr;23(4):648-653. doi: 10.1016/j.bbmt.2017.01.068. Epub 2017 Jan 10.

14.

Single institution experience with G-CSF mobilized T-cell replete haploidentical hematopoietic cell transplantation.

Huselton E, Slade M, DiPersio JF, Westervelt P, Vij R, Uy GL, Fehniger TA, Abboud CN, Gao F, Schroeder MA, Romee R.

Bone Marrow Transplant. 2017 May;52(5):769-771. doi: 10.1038/bmt.2016.354. Epub 2017 Jan 9. No abstract available.

PMID:
28067881
15.

Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.

Krysiak K, Gomez F, White BS, Matlock M, Miller CA, Trani L, Fronick CC, Fulton RS, Kreisel F, Cashen AF, Carson KR, Berrien-Elliott MM, Bartlett NL, Griffith M, Griffith OL, Fehniger TA.

Blood. 2017 Jan 26;129(4):473-483. doi: 10.1182/blood-2016-07-729954. Epub 2016 Nov 14.

16.

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ.

N Engl J Med. 2016 Nov 24;375(21):2023-2036. doi: 10.1056/NEJMoa1605949.

17.

Cytokine-Induced Memory-Like Differentiation Enhances Unlicensed Natural Killer Cell Antileukemia and FcγRIIIa-Triggered Responses.

Wagner JA, Berrien-Elliott MM, Rosario M, Leong JW, Jewell BA, Schappe T, Abdel-Latif S, Fehniger TA.

Biol Blood Marrow Transplant. 2017 Mar;23(3):398-404. doi: 10.1016/j.bbmt.2016.11.018. Epub 2016 Nov 25.

18.

Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide.

Goldsmith SR, Slade M, DiPersio JF, Westervelt P, Lawrence SJ, Uy GL, Abboud CN, Vij R, Schroeder MA, Fehniger TA, Dubberke ER, Trinkaus K, Romee R.

Haematologica. 2016 Nov;101(11):e465-e468. Epub 2016 Jul 21. No abstract available.

19.

Harnessing NK Cell Memory for Cancer Immunotherapy.

Fehniger TA, Cooper MA.

Trends Immunol. 2016 Dec;37(12):877-888. doi: 10.1016/j.it.2016.09.005. Epub 2016 Oct 21. Review.

20.

Mir-223 regulates the number and function of myeloid-derived suppressor cells in multiple sclerosis and experimental autoimmune encephalomyelitis.

Cantoni C, Cignarella F, Ghezzi L, Mikesell B, Bollman B, Berrien-Elliott MM, Ireland AR, Fehniger TA, Wu GF, Piccio L.

Acta Neuropathol. 2017 Jan;133(1):61-77. doi: 10.1007/s00401-016-1621-6. Epub 2016 Oct 4.

21.

Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.

Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, Leong JW, Abdel-Latif S, Schneider SE, Willey S, Neal CC, Yu L, Oh ST, Lee YS, Mulder A, Claas F, Cooper MA, Fehniger TA.

Sci Transl Med. 2016 Sep 21;8(357):357ra123. doi: 10.1126/scitranslmed.aaf2341.

22.

Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans.

Xiao DY, Luo S, O'Brian K, Sanfilippo KM, Ganti A, Riedell P, Lynch RC, Liu W, Kahl BS, Cashen AF, Fehniger TA, Carson KR.

J Natl Cancer Inst. 2016 Jul 5;108(11). doi: 10.1093/jnci/djw145. Print 2016 Nov.

23.

Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated.

Abboud R, Keller J, Slade M, DiPersio JF, Westervelt P, Rettig MP, Meier S, Fehniger TA, Abboud CN, Uy GL, Vij R, Trinkaus KM, Schroeder MA, Romee R.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1851-1860. doi: 10.1016/j.bbmt.2016.06.010. Epub 2016 Jun 16.

24.

Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia: A Retrospective Single-Center Review.

Rashidi A, DiPersio JF, Westervelt P, Vij R, Schroeder MA, Cashen AF, Fehniger TA, Romee R.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1696-1701. doi: 10.1016/j.bbmt.2016.05.010. Epub 2016 May 17.

25.

Human Adaptive Natural Killer Cells: Beyond NKG2C.

Wagner JA, Fehniger TA.

Trends Immunol. 2016 Jun;37(6):351-353. doi: 10.1016/j.it.2016.05.001. Epub 2016 May 11.

26.

HLA disparity is not inconsequential in peripheral blood T-replete haploidentical hematopoietic stem cell transplantation.

Rashidi A, DiPersio JF, Westervelt P, Abboud CN, Schroeder MA, Pusic I, Cashen AF, Fehniger TA, Romee R.

Bone Marrow Transplant. 2016 Sep;51(9):1275-8. doi: 10.1038/bmt.2016.117. Epub 2016 May 9. No abstract available.

PMID:
27159170
27.

Transcriptional and post-transcriptional regulation of NK cell development and function.

Leong JW, Wagner JA, Ireland AR, Fehniger TA.

Clin Immunol. 2017 Apr;177:60-69. doi: 10.1016/j.clim.2016.03.003. Epub 2016 Mar 3. Review.

28.

The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.

Rosario M, Liu B, Kong L, Collins LI, Schneider SE, Chen X, Han K, Jeng EK, Rhode PR, Leong JW, Schappe T, Jewell BA, Keppel CR, Shah K, Hess B, Romee R, Piwnica-Worms DR, Cashen AF, Bartlett NL, Wong HC, Fehniger TA.

Clin Cancer Res. 2016 Feb 1;22(3):596-608. doi: 10.1158/1078-0432.CCR-15-1419. Epub 2015 Sep 30.

29.

Improving natural killer cell cancer immunotherapy.

Berrien-Elliott MM, Romee R, Fehniger TA.

Curr Opin Organ Transplant. 2015 Dec;20(6):671-80. doi: 10.1097/MOT.0000000000000243. Review.

30.

Memory NK Cells Take Out the (Mitochondrial) Garbage.

Wagner JA, Fehniger TA.

Immunity. 2015 Aug 18;43(2):218-20. doi: 10.1016/j.immuni.2015.08.009.

31.

MicroRNA-15/16 Antagonizes Myb To Control NK Cell Maturation.

Sullivan RP, Leong JW, Schneider SE, Ireland AR, Berrien-Elliott MM, Singh A, Schappe T, Jewell BA, Sexl V, Fehniger TA.

J Immunol. 2015 Sep 15;195(6):2806-17. doi: 10.4049/jimmunol.1500949. Epub 2015 Aug 12.

32.

Human Cytokine-Induced Memory-Like Natural Killer Cells.

Berrien-Elliott MM, Wagner JA, Fehniger TA.

J Innate Immun. 2015;7(6):563-71. doi: 10.1159/000382019. Epub 2015 Apr 30. Review.

33.

Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients.

Vu K, Manjappa S, DiPersio JF, Gao F, Westervelt P, Vij R, Stockerl-Goldstein KE, Uy GL, Abboud CN, Schroeder MA, Fehniger TA, Cashen AF, Romee R.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1425-30. doi: 10.1016/j.bbmt.2015.03.022. Epub 2015 Mar 31.

34.

PTEN regulates natural killer cell trafficking in vivo.

Leong JW, Schneider SE, Sullivan RP, Parikh BA, Anthony BA, Singh A, Jewell BA, Schappe T, Wagner JA, Link DC, Yokoyama WM, Fehniger TA.

Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):E700-9. doi: 10.1073/pnas.1413886112. Epub 2015 Feb 2.

35.

Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma.

Carson KR, Riedell P, Lynch R, Nabhan C, Wildes TM, Liu W, Ganti A, Roop R, Sanfilippo KM, O'Brian K, Liu J, Bartlett NL, Cashen A, Wagner-Johnston N, Fehniger TA, Colditz GA.

J Geriatr Oncol. 2015 May;6(3):211-8. doi: 10.1016/j.jgo.2015.01.003. Epub 2015 Jan 19.

36.

microRNA management of NK-cell developmental and functional programs.

Leong JW, Sullivan RP, Fehniger TA.

Eur J Immunol. 2014 Oct;44(10):2862-8. doi: 10.1002/eji.201444798. Epub 2014 Sep 16. Review.

37.

Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer.

Romee R, Leong JW, Fehniger TA.

Scientifica (Cairo). 2014;2014:205796. doi: 10.1155/2014/205796. Epub 2014 Jun 25. Review.

38.

Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes.

Bhamidipati PK, DiPersio JF, Stokerl-Goldstein K, Rashidi A, Gao F, Uy GL, Westervelt P, Vij R, Schroeder MA, Abboud CN, Keller JW, Fehniger TA, Romee R.

Bone Marrow Transplant. 2014 Aug;49(8):1124-6. doi: 10.1038/bmt.2014.108. Epub 2014 May 19. No abstract available.

PMID:
24842528
39.

Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells.

Leong JW, Chase JM, Romee R, Schneider SE, Sullivan RP, Cooper MA, Fehniger TA.

Biol Blood Marrow Transplant. 2014 Apr;20(4):463-73. doi: 10.1016/j.bbmt.2014.01.006. Epub 2014 Jan 13.

40.

MicroRNA-155 tunes both the threshold and extent of NK cell activation via targeting of multiple signaling pathways.

Sullivan RP, Fogel LA, Leong JW, Schneider SE, Wong R, Romee R, Thai TH, Sexl V, Matkovich SJ, Dorn GW 2nd, French AR, Fehniger TA.

J Immunol. 2013 Dec 15;191(12):5904-13. doi: 10.4049/jimmunol.1301950. Epub 2013 Nov 13.

41.

Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen.

Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, DiPersio JF, Uy GL, Westervelt P, Liu J, Schroeder MA, Vij R, Abboud CN, Fehniger TA, Cashen AF, Pusic I, Jacoby M, Meera SJ, Romee R.

Biol Blood Marrow Transplant. 2014 Jan;20(1):46-52. doi: 10.1016/j.bbmt.2013.10.003. Epub 2013 Oct 10.

42.

Extracellular microRNAs turn on NK cells via TLR1.

Fehniger TA.

Blood. 2013 Jun 6;121(23):4612-3. doi: 10.1182/blood-2013-04-497594. No abstract available.

43.

"AbroGATAed" human NK cell development.

Fehniger TA.

Blood. 2013 Apr 4;121(14):2579-80. doi: 10.1182/blood-2013-02-483362. No abstract available.

44.

MicroRNA regulation of natural killer cells.

Sullivan RP, Leong JW, Fehniger TA.

Front Immunol. 2013 Feb 28;4:44. doi: 10.3389/fimmu.2013.00044. eCollection 2013.

45.

Unraveling the molecular events leading to the genesis of large granular lymphocytic leukemia reveals a new treatment strategy.

Fehniger TA.

Haematologica. 2013 Feb;98(2):159. doi: 10.3324/haematol.2013.084236. No abstract available.

46.

Natural killer cell regulation by microRNAs in health and disease.

Leong JW, Sullivan RP, Fehniger TA.

J Biomed Biotechnol. 2012;2012:632329. doi: 10.1155/2012/632329. Epub 2012 Nov 19. Review.

47.

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.

Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZ, Alachkar H, Maharry K, Nicolet D, Mrózek K, Walker A, Eiring AM, Whitman SP, Becker H, Perrotti D, Wu LC, Zhao X, Fehniger TA, Vij R, Byrd JC, Blum W, Lee LJ, Caligiuri MA, Bloomfield CD, Garzon R, Marcucci G.

Blood. 2013 Jan 3;121(1):159-69. doi: 10.1182/blood-2012-05-428573. Epub 2012 Oct 25.

48.

Cytokine activation induces human memory-like NK cells.

Romee R, Schneider SE, Leong JW, Chase JM, Keppel CR, Sullivan RP, Cooper MA, Fehniger TA.

Blood. 2012 Dec 6;120(24):4751-60. doi: 10.1182/blood-2012-04-419283. Epub 2012 Sep 14.

49.

MicroRNA-deficient NK cells exhibit decreased survival but enhanced function.

Sullivan RP, Leong JW, Schneider SE, Keppel CR, Germino E, French AR, Fehniger TA.

J Immunol. 2012 Apr 1;188(7):3019-30. doi: 10.4049/jimmunol.1102294. Epub 2012 Feb 29.

50.

T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome.

Weisdorf D, Cooley S, Devine S, Fehniger TA, DiPersio J, Anasetti C, Waller EK, Porter D, Farag S, Drobyski W, Defor T, Haagenson M, Curtsinger J, Miller J.

Biol Blood Marrow Transplant. 2012 Jun;18(6):937-43. doi: 10.1016/j.bbmt.2011.11.024. Epub 2011 Dec 7.

Supplemental Content

Loading ...
Support Center